Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach

Autor: Rachel E. Young, Katherine M. Nelson, Samuel I. Hofbauer, Tara Vijayakumar, Mohamad-Gabriel Alameh, Drew Weissman, Charalampos Papachristou, Jason P. Gleghorn, Rachel S. Riley

Publikováno v: Bioactive Materials, Vol 34, Iss , Pp 125-137 (2024)

Ionizable lipid nanoparticles (LNPs) have gained attention as mRNA delivery platforms for vaccination against COVID-19 and for protein replacement therapies. LNPs enhance mRNA stability, circulation time, cellular uptake, and preferential delivery to

Externí odkaz: https://doaj.org/article/030cc556d30340f79b8eba32bbbbe63c

Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)

Autor: Hamideh Parhiz, Jacob S. Brenner, Priyal N. Patel, Tyler E. Papp, Hamna Shahnawaz, Qin Li, Ruiqi Shi, Marco E. Zamora, Amir Yadegari, Oscar A. Marcos-Contreras, Ambika Natesan, Norbert Pardi, Vladimir V. Shuvaev, Raisa Kiseleva, Jacob W. Myerson, Thomas Uhler, Rachel S. Riley, Xuexiang Han, Michael J. Mitchell, Kieu Lam, James Heyes, Drew Weissman, Vladimir R. Muzykantov

Publikováno v: Journal of Controlled Release

Current nucleoside-modified RNA lipid nanoparticle (modmRNA-LNP) technology has successfully paved the way for the highest clinical efficacy data from next-generation vaccinations against SARS-CoV-2 during the COVID-19 pandemic. However, such modmRNA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b3bb75c1bfa179ab971c5c700797c73
https://doi.org/10.1016/j.jconrel.2021.12.027

Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas

Autor: Paul Zolkind, Gavin P. Dunn, Ann Marie Egloff, Erica K. Barnell, Ravindra Uppaluri, Obi L. Griffith, Tenny Mudianto, Tusar Giri, Rachel S. Riley, Malachi Griffith, Jason Webb, Zachary L. Skidmore, Douglas Adkins, Katie M. Campbell, Ibrahim Ozgenc

Publikováno v: Clin Cancer Res

Purpose: In a head and neck squamous cell carcinoma (HNSCC) “window of opportunity” clinical trial, we reported that trametinib reduced MEK-Erk1/2 activation and resulted in tumor responses in a subset of patients. Here, we investigated resistanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fd48b802ac11aede37c588462911429
https://doi.org/10.1158/1078-0432.ccr-19-4179

Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening

Autor: Amanda Chung, Rachel S. Riley, Rui Zhang, Margaret M. Billingsley, Lili Wang, Roman Spektor, Pedro P.G. Guimarães, Mingchee Tan, Rakan El-Mayta, James M. Wilson, Michael J. Mitchell

Publikováno v: J Control Release

Messenger RNA (mRNA) has recently emerged as a promising class of nucleic acid therapy with the potential to induce protein production to treat and prevent a range of diseases. While significant progress has been made in the design of in vitro-transc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8727ddebb2c77175384448c4ddf85cc6
https://doi.org/10.1016/j.jconrel.2019.10.028

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

Autor: Ryan S. Jackson, Mackenzie Daly, Jason I. Kass, Tiantian Li, Evisa Gjini, Youstina Hanna, Ian S. Hagemann, Liye Zhou, Douglas Adkins, Trevor J. Pugh, Gavin P. Dunn, Jessica Ley, Wade L. Thorstad, Glenn J. Hanna, Scott J. Rodig, Rachel S. Riley, Randal C. Paniello, Malachi Griffith, David Mulder, Tianxiang Lin, Ana Lako, Nicholas C. Spies, Matthew D. Stachler, Jason T. Rich, Rebecca D. Chernock, Loren S. Michel, Ravindra Uppaluri, Dorina Kallogjeri, Patrik Pipkorn, Robert I. Haddad, Vickie Y. Jo, Brian Nussenbaum, Jonathan D. Schoenfeld, Iulia Cirlan, Jay F. Piccirillo, Peter Oppelt, Paul Zolkind, Ann Marie Egloff, Obi L. Griffith, Zachary L. Skidmore, Erica K. Barnell, Tenny Mudianto, Katie M. Campbell

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 19
Clin Cancer Res
Int J Radiat Oncol Biol Phys

SUMMARYBackgroundPembrolizumab improved survival of patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this phase 2 trial were to determine if pembrolizumab administered to patients with resectable locall

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8902376009ddebcea905e680e2c23c75
https://doi.org/10.1101/2020.03.18.20037846